Cyanide toxicity in smoke inhalation

Overview

Hydrogen cyanide (HCN) is generated by combustion of nitrogen-containing synthetic polymers including plastics, textiles, and insulation materials commonly found in residential and commercial structures ^[2][4]. Cyanide poisoning is common among fire victims, with studies reporting toxic blood cyanide levels in a substantial proportion of patients with enclosed-space smoke inhalation ^[4]. Cyanide poisoning acts synergistically with carbon monoxide (CO), lowering the lethal threshold for both toxins and contributing to the high early mortality seen in enclosed-space fires ^[8].

Unlike CO, cyanide levels cannot be obtained rapidly enough to guide acute management decisions. Clinical diagnosis relies on the exposure scenario, hemodynamic instability, altered mental status, and elevated serum lactate in the setting of smoke inhalation ^[2][4].

Pathophysiology

Cyanide binds to the ferric iron (Fe3+) of cytochrome c oxidase (Complex IV) in the mitochondrial electron transport chain, halting oxidative phosphorylation ^[8]. Key consequences include:

• Cellular asphyxiation: Cells cannot utilize oxygen despite adequate delivery, forcing anaerobic metabolism and rapid lactate accumulation.
• Lactic acidosis: Profound metabolic acidosis develops as anaerobic glycolysis becomes the primary energy source.
• Cardiovascular collapse: Myocardial depression and vasodilation lead to refractory hypotension and cardiac arrest.
• Neurotoxicity: The central nervous system is highly sensitive to disrupted oxidative metabolism, producing early altered mental status, seizures, and coma.

The lethal dose of inhaled HCN is low (100-300 ppm for brief exposures), and death can occur within minutes of high-concentration exposure ^[4].

Clinical Presentation

Cyanide toxicity presents with nonspecific findings that overlap substantially with CO poisoning ^[2][4]:

• Altered mental status ranging from confusion to coma
• Unexplained hypotension (systolic blood pressure less than 90 mmHg)
• Seizures
• Cardiac arrest or arrhythmias
• Severe lactic acidosis (lactate 8 mmol/L or greater strongly suggests cyanide involvement)

The classic "bitter almond" odor is detectable by only 40-60% of the population and is unreliable as a diagnostic sign ^[4].

Diagnosis

Cyanide poisoning cannot be confirmed in real time; serum cyanide assays take hours and are not available at most institutions ^[2][8]. The diagnosis is therefore clinical and empiric. The European expert consensus identifies four findings suggesting cyanide toxicity in fire victims ^[4]:

1. History of enclosed-space fire
2. Any alteration in level of consciousness
3. Cardiovascular instability, particularly unexplained hypotension
4. Elevated plasma lactate

A serum lactate of 8 mmol/L or greater in a smoke inhalation victim has high specificity for significant cyanide exposure ^[1][4]. COHb levels greater than 10% in the setting of enclosed-space fire further increase the probability of concurrent cyanide poisoning ^[8].

Treatment

Hydroxocobalamin

Hydroxocobalamin (Cyanokit) is the preferred cyanide antidote and is the only agent without a serious adverse cardiovascular profile ^[1][2][4]. It chelates cyanide by binding to CN- ions to form cyanocobalamin (vitamin B12), which is renally excreted.

• Dose: 5 g IV in adults, infused over 15 minutes. May repeat once if clinically indicated.
• Pediatric dosing: 70 mg/kg IV (standard adult vials can cause overdose in children if not weight-adjusted) ^[4].
• Timing: Empiric prehospital or emergency department administration is recommended for high-risk presentations. A prospective study of 69 fire victims found 67% survival among patients with confirmed cyanide poisoning treated with hydroxocobalamin ^[10].

Safety profile: A 2024 retrospective cohort study from Los Angeles General Medical Center (36 hydroxocobalamin-treated patients, 32 matched controls) found no significant differences in methemoglobin levels, lactate clearance, mortality, or kidney function, supporting the safety of hydroxocobalamin in the burn population ^[6]. Expected adverse effects include chromaturia (red-orange urine) and transient skin erythema. Interference with co-oximetry and standard laboratory colorimetric assays is well documented ^[6].

Outcomes: A retrospective study comparing 138 hydroxocobalamin-treated patients with 135 historical controls found no mortality difference, but hydroxocobalamin was associated with lower pneumonia rates (23% vs 49%, P < 0.01), fewer ventilator days (4 vs 7, P < 0.01), and shorter ICU stay (6 vs 10 days, P = 0.03) ^[3].

Alternative Antidotes

The traditional cyanide antidote kit (amyl nitrite, sodium nitrite, sodium thiosulfate) induces methemoglobin formation to bind cyanide. This approach carries risks of hypotension and impaired oxygen-carrying capacity that are particularly dangerous in the CO-poisoned patient, where methemoglobin further reduces functional hemoglobin ^[2][4]. These agents are generally considered second-line in smoke inhalation scenarios.

Prehospital Administration

A scoping review of 512 patients treated with hydroxocobalamin for HCN toxicity secondary to smoke inhalation found that 45.9% received it prehospitally ^[7]. Among 482 patients with known survival status, 66% survived to hospital discharge ^[7]. However, prehospital hydroxocobalamin use remains uncommon in the United States; a survey of EMS providers found only 38% reported prehospital utilization of any cyanide antidote ^[9]. Defined clinical criteria (hypotension, altered mentation, seizures, cardiac arrest) may help standardize indications and reduce unnecessary use ^[5].

Controversies and Evidence Gaps

• Routine empiric hydroxocobalamin administration for all smoke inhalation victims versus targeted use for high-risk presentations remains debated. Cost (approximately $800-1000 per dose) and reports of acute kidney injury in some studies factor into institutional protocols ^[1].
• The relationship between hydroxocobalamin and acute kidney injury is confounded by the severity of underlying injury. Observational studies show mixed findings, and no causal mechanism has been established ^[1][6].
• Optimal clinical criteria for initiating empiric treatment are not standardized. Proposed algorithms vary across institutions and EMS systems ^[1][5].
• Prospective RCTs of hydroxocobalamin in fire victims are lacking; evidence is primarily observational ^[7].

References

[1] Kamta J et al. "Evaluation of hydroxocobalamin use for the treatment of suspected cyanide toxicity secondary to smoke inhalation." Burns 2023;50(1):157-166. PMID: 37777459. [2] O'Brien DJ et al. "Empiric management of cyanide toxicity associated with smoke inhalation." Prehosp Disaster Med 2011;26(5):374-82. PMID: 22336184. [3] Nguyen L et al. "Utility and outcomes of hydroxocobalamin use in smoke inhalation patients." Burns 2016;43(1):107-113. PMID: 27554631. [4] Anseeuw K et al. "Cyanide poisoning by fire smoke inhalation: a European expert consensus." Eur J Emerg Med 2013;20(1):2-9. PMID: 22828651. [5] Cumpston KL et al. "Evaluation of prehospital hydroxocobalamin use in the setting of smoke inhalation." Am J Emerg Med 2021;50:365-368. PMID: 34461397. [6] Stanton EW et al. "Hydroxocobalamin is not associated with methemoglobinemia in patients with inhalation injury and suspected cyanide toxicity and a proposed algorithm for hydroxocobalamin administration." Burns 2024;50(7):1746-1751. PMID: 38760187. [7] Dunne R et al. "Intravenous Hydroxocobalamin for Cyanide Poisoning From Smoke Inhalation: A Comprehensive Scoping Review." J Am Coll Emerg Physicians Open 2026;7(2):100340. PMID: 41799837. [8] Huzar TF et al. "Carbon monoxide and cyanide toxicity: etiology, pathophysiology and treatment in inhalation injury." Expert Rev Respir Med 2013;7(2):159-70. PMID: 23547992. [9] Purvis MV et al. "Prehospital hydroxocobalamin for inhalation injury and cyanide toxicity in the United States - analysis of a database and survey of EMS providers." Ann Burns Fire Disasters 2017;30(2):126-128. PMID: 29021725. [10] Borron SW et al. "Prospective study of hydroxocobalamin for acute cyanide poisoning in smoke inhalation." Ann Emerg Med 2007;49(6):794-801. PMID: 17481777.